Hercules Capital, Inc.

Equities

HTGC

US4270965084

Investment Management & Fund Operators

Market Closed - Nyse Other stock markets 04:00:02 2024-04-17 pm EDT			5-day change	1st Jan Change
18.16 ^USD	+0.94%		-0.93%	+8.94%

Apr. 03	KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. for $100 million.	CI
Mar. 26	Bluebird bio to Restate Financial Statements; Shares Fall	MT

Alladapt Immunotherapeutics, Inc. announced that it expects to receive $50 million in funding

August 29, 2022

Alladapt Immunotherapeutics, Inc. announced that it has entered into a term loan agreement for the gross proceeds of $50 million on August 30, 2022. The transaction will include participation from new investor Hercules Capital, Inc.

Latest news about Hercules Capital, Inc.

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. for $100 million.	Apr. 02	CI
Bluebird bio to Restate Financial Statements; Shares Fall	Mar. 26	MT
JMP Securities Adjusts Hercules Capital Price Target to $19 From $18, Maintains Market Outperform Rating	Mar. 26	MT
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon	Mar. 18	MT
Sector Update: Health Care	Mar. 18	MT
Bluebird bio Secures $175 Million Term Loan Facility	Mar. 18	MT
Health Data Vision, Inc. announced that it has received $65 million in funding from Hercules Capital, Inc.	Feb. 25	CI
Piper Sandler Raises Price Target on Hercules Capital to $20 From $18.50, Maintains Overweight Rating	Feb. 16	MT
Hercules Capital Posts Increased Q4 Net, Total Investment Income	Feb. 15	MT
Transcript : Hercules Capital, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Hercules Capital, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Hercules Capital, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Wheat Futures Fall as Russian Export Prices Sink -- Daily Grain Highlights	Feb. 15	DJ
Hercules Capital Declares Q4 Supplemental Cash Distribution of $0.08 a Share, Payable March 6 to Shareholders of Record Feb. 28	Feb. 13	MT
Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024	Feb. 13	CI
Hercules Capital Announces New Supplemental Cash Distribution of $0.32 Per Share, Payment on March 6, 2024	Feb. 13	CI
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million.	Feb. 05	CI
Wells Fargo Adjusts Price Target on Hercules Capital to $18 From $17, Maintains Overweight Rating	Jan. 29	MT
North American Morning Briefing : Central Bankers -2-	Jan. 17	DJ
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Traders Exercise Caution	Jan. 02	MT
Verona Pharma Secures $400 Million Debt Facility With Oxford Finance, Hercules Capital	Jan. 02	MT
UBS Initiates Coverage on Hercules Capital With Neutral Rating, $17 Price Target	Nov. 21	MT
Vida Health, Inc. announced that it has received $28.5 million in funding from Canvas Management Company, L.L.C., Ally Bridge Group, General Atlantic Service Company, L.P., Hercules Capital, Inc. and other investors	Nov. 08	CI
Hercules Capital's Q3 Net Investment Income Rises	Nov. 02	MT
Transcript : Hercules Capital, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02

Chart Hercules Capital, Inc.

Duration

Period

More charts

Company Profile

Hercules Capital, Inc. is a specialty finance company. The Company is focused on providing financing solutions to venture capital-backed and institutional-backed companies in a variety of technology, life sciences and sustainable and renewable technology industries. It is structured as an internally managed, non-diversified, closed-end investment company. Its business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments in primarily Structured Debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology related industries at attractive yields. It invests in a range of companies active in the technology industry sub-sectors characterized by products or services that require advanced technologies, including, computer software and hardware, networking systems, semiconductors, semiconductor capital equipment, information technology infrastructure and others.

Sector

Investment Management & Fund Operators

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hercules Capital, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.16 USD

Average target price

18.67 USD

Spread / Average Target

+2.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Venture Capital

	1st Jan change	Capi.
HERCULES CAPITAL, INC.	+8.94%	2.91B
UMBRA COMPANIES INC.	+31.41%	12.02B
HBM HEALTHCARE INVESTMENTS AG	+1.97%	1.41B
OCTOPUS TITAN VCT PLC	-10.72%	1.22B
CION INVESTMENT CORPORATION	-2.48%	594M
VERUSA HOLDING	+46.95%	567M
MOLTEN VENTURES PLC	-22.19%	511M
OCTOPUS APOLLO VCT PLC	-4.17%	492M
WOORI TECHNOLOGY INVESTMENT CO., LTD	+36.49%	495M
BRITISH SMALLER COMPANIES VCT PLC	+5.84%	304M

Venture Capital